Grünenthal GmbH is an independent, family-owned pharmaceutical company founded in 1946 and headquartered in Germany. The company's core focus is pain management and related diseases, operating with a stated vision of "a World Free of Pain." It employs approximately 4,100 people worldwide and reported revenue of 1.8 billion euros in 2025.
The company maintains a commercial presence in 28 countries across Europe, Latin America, and the US, with products sold in around 100 countries. Its portfolio comprises 13 brands across six therapeutic areas. Notable products include Tramal®, a central-acting analgesic launched in 1977 that became one of the most frequently prescribed in its class globally, and Palexia® retard (tapentadol), the first innovative molecule in the centrally acting analgesic class approved in more than 25 years. The company has also acquired key brands such as Nexium®, Vimovo®, and Qutenza®.
Grünenthal is recognized as an ESG industry leader and states a commitment to conducting business responsibly and creating positive impact for society.
